Jian-Qiang Wang1, Guo-Rong Wu2, Zheng Wang2, Xiao-Ping Dai2, Xiang-Rong Li2. 1. Department of Critical Care Medicine, Jintan Hospital, Jiangsu University, Jiangsu, PR China. Electronic address: wwjq198@sina.com. 2. Department of Critical Care Medicine, Jintan Hospital, Jiangsu University, Jiangsu, PR China.
Abstract
BACKGROUND: The effect of statin treatment on the long-term prognosis in patients with chronic heart failure (CHF) remains uncertain. This study aimed to answer the question by a meta-analysis. METHODS: The Cochrane databases, MEDLINE and EMBASE, were systematically searched. The eligibility of prospective studies that assigned CHF patients to receive statin treatment and a control (no statin treatment), had defined prognostic outcomes as primary endpoint, and had a minimal follow-up of 12 months was determined. RESULTS: Fifteen studies involving 45,110 patients were included in the analysis. Additional statin treatment was associated with reduced all-cause mortality (risk ratios [RR] = 0.71, 95% confidence intervals [CI] 0.61-0.83) and reduced rehospitalisation rate for heart failure (RR = 0.84, 95% CI 0.74-0.96). Statin treatment, however, had little impact on pump failure mortality, cardiovascular mortality, and sudden cardiac death. Atorvastatin treatment appeared to facilitate to reduce all-cause mortality (lnRR = 0.61, p = 0.05) and rehospitalisation for heart failure (lnRR = 0.44, p = 0.04) compared with non-atorvastatin therapy. CONCLUSIONS: Based on the available data, statins persistently decreased all-cause mortality and the incidence of rehospitalisation for heart failure in CHF patients, and the benefits might be partially associated with use of specific statin.
BACKGROUND: The effect of statin treatment on the long-term prognosis in patients with chronic heart failure (CHF) remains uncertain. This study aimed to answer the question by a meta-analysis. METHODS: The Cochrane databases, MEDLINE and EMBASE, were systematically searched. The eligibility of prospective studies that assigned CHFpatients to receive statin treatment and a control (no statin treatment), had defined prognostic outcomes as primary endpoint, and had a minimal follow-up of 12 months was determined. RESULTS: Fifteen studies involving 45,110 patients were included in the analysis. Additional statin treatment was associated with reduced all-cause mortality (risk ratios [RR] = 0.71, 95% confidence intervals [CI] 0.61-0.83) and reduced rehospitalisation rate for heart failure (RR = 0.84, 95% CI 0.74-0.96). Statin treatment, however, had little impact on pump failure mortality, cardiovascular mortality, and sudden cardiac death. Atorvastatin treatment appeared to facilitate to reduce all-cause mortality (lnRR = 0.61, p = 0.05) and rehospitalisation for heart failure (lnRR = 0.44, p = 0.04) compared with non-atorvastatin therapy. CONCLUSIONS: Based on the available data, statins persistently decreased all-cause mortality and the incidence of rehospitalisation for heart failure in CHFpatients, and the benefits might be partially associated with use of specific statin.
Authors: Lauren N Strand; Rebekah L Young; Alain G Bertoni; David A Bluemke; Gregory L Burke; Joao A Lima; Nona Sotoodehnia; Bruce M Psaty; Robyn L McClelland; Susan R Heckbert; Joseph A Delaney Journal: Pharmacoepidemiol Drug Saf Date: 2018-01-30 Impact factor: 2.890